Your session is about to expire
← Back to Search
Pre-Surgery Olaparib for Ovarian Cancer (NEO Trial)
NEO Trial Summary
This trial will study how well olaparib works as a neoadjuvant treatment for ovarian, primary peritoneal, or fallopian tube cancer.
NEO Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowNEO Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 154 Patients • NCT02184195NEO Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My hearing loss is not severe.My last platinum-based treatment was effective.I am 18 years old or older.I have been mostly active and able to carry on all pre-disease activities without restriction in the past week.My organs and bone marrow are functioning normally.I haven't had any other cancer besides this one in the last 2 years.My cancer is a recurrent high-grade serous type in the ovary, peritoneum, or fallopian tube.My condition is considered operable for tumor removal.I have received platinum-based chemotherapy before.I am willing and able to follow the study's schedule and procedures.I am not taking strong medications that affect liver enzyme CYP3A4.My condition has not worsened for at least 6 months.I haven't taken any cancer drugs or been in a study for new treatments in the last 4 weeks.I do not have any serious, uncontrolled health issues or infections.My condition allows for a biopsy before surgery.I have not had radiation therapy in the last 4 weeks.My cancer has spread to my brain.I have lasting side effects from cancer treatment, but not hair loss.I do not have active hepatitis B or C.I have been diagnosed with myelodysplastic syndrome or acute myeloid leukemia.I have been treated with a PARP inhibitor before.I have not received a live vaccine in the last 30 days.I am not currently on any other cancer treatments like immunotherapy.I am not taking strong medications that affect liver enzymes.I cannot swallow pills or have a stomach condition that affects medication absorption.
- Group 1: Olaparib Prior to Surgery, Chemotherapy/Olaparib Post Surgery
- Group 2: Olaparib Prior to Surgery and Post Surgery
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the sample size of this research endeavor?
"This medical trial is no longer recruiting. It was posted on July 19th 2016 and last updated on May 9th 2022, so you need to look elsewhere if you are interested in taking part in a study. There are 499 studies that involve debulking surgical procedures currently open for enrollment and 349 trials related to Olaparib accepting participants."
What earlier experiments utilized Olaparib in their research?
"Currently, there are 349 clinical trials that explore the effectiveness and safety of Olaparib with 87 studies in Phase 3. Phoenix, Arizona is home to most of these experiments but 30254 other sites worldwide also conduct research for this drug."
How many medical centers are currently administering this experiment?
"Currently, this research project is enrolling participants from 5 different sites. These include locations within Ottawa, Montréal and Calgary as well as other regional centres. To reduce the burden of travel we suggest selecting a site near you if possible."
What diseases does Olaparib commonly target?
"Olaparib is a viable option for treating advance directives, ovarian malignancies, and primary peritoneal cancer."
How reliable has Olaparib been demonstrated to be for human use?
"The safety of Olaparib has been judged to be a 2 on the scale, as this is an early clinical trial with limited data regarding efficacy, but some evidence pointing towards its safety."
Is there currently an enrollment process for participants of this experiment?
"According to the clinicaltrials.gov database, this medical trial is no longer recruiting candidates though it was initially posted in July 19th 2016 and last updated on May 9th 2022. However, there are 848 other studies offering participant enrolment currently."
Share this study with friends
Copy Link
Messenger